HCM
ABUS icon

Highbridge Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Highbridge Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,426
Closed -$147K – 1484
2015
Q2 		$147K Buy
+12,426
New +$189K ﹤0.01% 1322

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Highbridge Capital Management's ABUS Position: Q3 2015 in Review

Highbridge Capital Management sold out of Arbutus Biopharma (ABUS) in Q3 2015, closing a stake of 12,426 shares — an estimated $147K sold.

Highbridge Capital Management first reported a position in ABUS in Q2 2015 and held it in 1 quarter. The position peaked at $147K in Q2 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q3 2015.

  • Highbridge Capital Management reported no remaining Arbutus Biopharma position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 12,426 Arbutus Biopharma shares in Q3 2015, an estimated $147K.
  • Highbridge Capital Management first reported a position in Arbutus Biopharma in Q2 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Arbutus Biopharma position peaked at $147K in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.